There are many informed shareholders that frequent this message board. I put these questions to all who would choose to respond.
The CABO bone mets response phenomenon has been clearly noted in trial for approx a year now. I am not a medically technical type, and it is sometimes a ROYAL stretch for me to understand the data, let alone understand the validation of proposed - and never before approved - surrogate endpoints.
Are you guys satisfied that EXEL is doing everything that can be technically accomplished to validate these extraordinary, unprecedented bone scan resolution findings...??
This appears to be the key to EXEL's future. It is the one thing that truly differentiates CABO from the rest...
Why would EXEL hire the world's most experienced oncology drug salesman unless they were confident they had a marketable product?
J. Scott Garland has a heck of a history in onco-drugs. Was he secured prematurely...or is Ol' J.Scott the harbinger of great stuff to come for all of us?